Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B

Figure 1 Flow chart of patient enrollment. ALT: Alanine aminotransferase.

Figure 2 Median changes in serum alanine aminotransferase values and cumulative rates of alanine aminotransferase normalization during the on-treatment period. A: Alanine aminotransferase (ALT) values; B: Cumulative rates of ALT normalization.

Figure 3 Decrement changes in serum hepatitis B virus DNA titer and cumulative rates of hepatitis B virus DNA non-detection during the on-treatment period. A: Hepatitis B virus (HBV) DNA decrement changes; B: HBV DNA non-detection rate.

Figure 4 Cumulative rates of hepatitis B e antigen clearance and hepatitis B e antigen seroconversion during the on-treatment period. A: Hepatitis B e antigen (HBeAg) clearance rate; B: HBeAg seroconversion rate.